The FDA has approved another formulation of insulin lispro—a type of rapid-acting human insulin analog—to improve glycemic control in adults and children aged 3 years or older with type 1 diabetes and in adults with type 2 diabetes. Marketed as Admelog, the product is a follow-on drug approved through an abbreviated pathway that relied in part on its similarity to Humalog, an insulin lispro approved in 1996.
Voelker R. New Human Insulin Analog Approved. JAMA. 2018;319(5):434. doi:10.1001/jama.2017.21720
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: